Since there is important new information for infertility patients to be disseminated, we decided to shorten the summer hiatus for the VOICE by, after all, publishing a July issue. This issue will, therefore, among other subjects, address the seemingly never-ending saga of preimplantation genetic screening (PGS), now suddenly given the new name preimplantation genetic testing for aneuploidy (PGT-A) by the American Society for Reproductive Medicine (ASRM), and by us, simply, given the acronym PGS 3.0. We will also address a previously only marginally discussed subject in the VOICE, which in recent months in chat-rooms, however, received increasing attention: the so-called “ovarian rejuvenation.”
In addition, we also have to again note the issue of nuclear transfer (i.e., 3-parent IVF), this time in attempts to treat infertility in older women, since colleagues here in New York City have gone public by announcing the utilization of this technique (without prior approval by the Food and Drug Administration) through a newly-formed start-up company at the startling average price of $100,000 per in vitro fertilization (IVF) cycle. With so much truly challenging news to comment on, we, simply, could not stay quiet in the month of July!
In this issue, we cover:
- The ultimate evidence from leading proponents of PGS that flipping a coin is as good as PGS 3.0 in determining embryo ploidy
- You must have heard recently about “OVARIAN REJUVENATION”
- Future fertility with polycystic ovary syndrome (PCOS)
- PGS is no more; Long live PGT-A!
- Commercializing three-parent babies
- In Focus: Blastocyst and trophectoderm